A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
Conditions: Chronic Kidney Disease; Chronic Renal FailureInterventions: Biological: Epoetin Hospira; Biological: Epogen (Amgen)Sponsor: Hospira, Inc.Completed - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2011 Category: Research Source Type: clinical trials
A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
Conditions: Chronic Renal Failure; Chronic Kidney DiseaseInterventions: Biological: Epoetin Hospira; Biological: Epogen AmgenSponsor: Hospira, Inc.Completed - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2011 Category: Research Source Type: clinical trials
An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic SyndromesInterventions: Drug: Group 2: Placebo; Drug: Group 1: Epoetin alfaSponsor: Janssen-Cilag International NVActive, not recruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 25, 2011 Category: Research Source Type: clinical trials
An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic SyndromesInterventions: Drug: Group 2: Placebo; Drug: Group 1: Epoetin alfaSponsors: Janssen-Cilag International NV; Janssen-Cilag International NVRecruiting - verified December 2012 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 23, 2011 Category: Research Source Type: clinical trials
